Study will test testosterone gel in hypogonadal men with diabetes

Article

Testosterone gel (AndroGel) 1% will be evaluated for its efficacy and safety as an adjunct to oral hypoglycemic therapy in men with type 2 diabetes and hypogonadism, according to its manufacturer, Solvay Pharmaceuticals, Inc.

Testosterone gel (AndroGel) 1% will be evaluated for its efficacy and safety as an adjunct to oral hypoglycemic therapy in men with type 2 diabetes and hypogonadism, according to its manufacturer, Solvay Pharmaceuticals, Inc.

The company has initiated a proof of concept trial, and patient recruitment is underway. The double-blind, parallel, randomized, placebo-controlled study will enroll 180 patients at about 55 U.S. sites. A study extension also is planned. Results will be collected and analyzed to develop a potential phase III clinical trial.

To be considered in the study, men must be between 30 and 80 years, have a diagnosis of type 2 diabetes, and have moderate control of their diabetes with oral hypoglycemic agents. Men also will be screened for low testosterone with a blood test for final study inclusion.

Related Videos
blur image background of corridor in hospital or clinic image | Image Credit @ whyframeshot - stock.adobe.com
Male and female surgeon performing surgery | Image Credit: © Georgii - stock.adobe.com
 Licensed   FILE #:  458906503  Preview Crop  Find Similar  Expand Image DIMENSIONS 8000 x 5333px FILE TYPE JPEG CATEGORY The Environment LICENSE TYPE Standard or Extended A lake in the shape of a recycling sign in the middle of untouched nature | Image Credit: © malp - stock.adobe.com
Dr. Mehmet Asim Bilen in an interview with Urology Times
Anne M. Suskind, MD, MS, FACS, FPMRS, answers a question during a Zoom video interview
blurred clinic hallway
Related Content
© 2024 MJH Life Sciences

All rights reserved.